United Therapeutics Co. (UTHR) Expected to Post Quarterly Sales of $372.32 Million

Share on StockTwits

Analysts expect that United Therapeutics Co. (NASDAQ:UTHR) will report sales of $372.32 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for United Therapeutics’ earnings. The highest sales estimate is $412.00 million and the lowest is $332.50 million. United Therapeutics posted sales of $445.50 million during the same quarter last year, which suggests a negative year-over-year growth rate of 16.4%. The business is expected to issue its next earnings report on Wednesday, October 24th.

According to Zacks, analysts expect that United Therapeutics will report full-year sales of $1.53 billion for the current year, with estimates ranging from $1.45 billion to $1.60 billion. For the next financial year, analysts forecast that the company will post sales of $1.22 billion, with estimates ranging from $1.11 billion to $1.42 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that cover United Therapeutics.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $1.41. United Therapeutics had a return on equity of 34.42% and a net margin of 40.87%. The firm had revenue of $444.50 million for the quarter, compared to the consensus estimate of $368.63 million. During the same quarter in the prior year, the business earned $4.37 earnings per share. The company’s revenue was up .0% compared to the same quarter last year.

A number of analysts have recently commented on UTHR shares. Wedbush set a $253.00 target price on United Therapeutics and gave the stock a “buy” rating in a research note on Thursday, September 27th. HC Wainwright set a $95.00 target price on United Therapeutics and gave the stock a “hold” rating in a research note on Monday, August 13th. BidaskClub upgraded United Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, September 18th. Zacks Investment Research downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Sunday, July 15th. Finally, Standpoint Research upgraded United Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, October 12th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $138.86.

Shares of UTHR traded down $2.88 during mid-day trading on Wednesday, reaching $122.95. The company had a trading volume of 317,191 shares, compared to its average volume of 327,836. United Therapeutics has a 52-week low of $100.57 and a 52-week high of $152.55. The company has a quick ratio of 4.35, a current ratio of 4.64 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $5.48 billion, a price-to-earnings ratio of 11.29, a PEG ratio of 28.40 and a beta of 1.21.

In other United Therapeutics news, Director Richard Giltner sold 3,240 shares of the stock in a transaction that occurred on Thursday, August 16th. The stock was sold at an average price of $129.38, for a total transaction of $419,191.20. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Christopher Causey sold 810 shares of the stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $119.00, for a total value of $96,390.00. Following the transaction, the director now owns 1,555 shares in the company, valued at approximately $185,045. The disclosure for this sale can be found here. Insiders have sold 4,860 shares of company stock worth $611,161 in the last quarter. 8.20% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the business. Legacy Financial Advisors Inc. purchased a new position in United Therapeutics during the second quarter worth approximately $107,000. Sun Life Financial INC purchased a new position in United Therapeutics during the second quarter worth approximately $198,000. Fox Run Management L.L.C. purchased a new position in United Therapeutics during the second quarter worth approximately $269,000. HL Financial Services LLC boosted its position in United Therapeutics by 32.1% during the second quarter. HL Financial Services LLC now owns 2,711 shares of the biotechnology company’s stock worth $307,000 after purchasing an additional 658 shares in the last quarter. Finally, Worldquant Millennium Quantitative Strategies LLC purchased a new position in United Therapeutics during the second quarter worth approximately $347,000. Institutional investors own 95.67% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Story: Rule of 72

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Covidien  Earns Daily Coverage Optimism Score of 2.00
Covidien Earns Daily Coverage Optimism Score of 2.00
Sovereign Hero  Tops 24-Hour Trading Volume of $0.00
Sovereign Hero Tops 24-Hour Trading Volume of $0.00
Ifoods Chain  Trading 29.6% Lower  Over Last 7 Days
Ifoods Chain Trading 29.6% Lower Over Last 7 Days
Cent JAPAN Rwy/ADR  Stock Rating Lowered by Zacks Investment Research
Cent JAPAN Rwy/ADR Stock Rating Lowered by Zacks Investment Research
Traders Sell JPMorgan Chase & Co.  on Strength
Traders Sell JPMorgan Chase & Co. on Strength
Investors Sell Vanguard FTSE Developed Markets ETF  on Strength
Investors Sell Vanguard FTSE Developed Markets ETF on Strength


© 2006-2018 Ticker Report